Research progress in risk factors of post-transplantation diabetes mellitus

Dong Junfeng; Xue Qiang; Teng Fei; Zhao Yuanyu; Yin Hao

doi:10.3969/j.issn.1674-7445.2023154

Volume 15 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2024 > 15(1): 145-150

Dong Junfeng, Xue Qiang, Teng Fei, et al. Research progress in risk factors of post-transplantation diabetes mellitus[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 145-150. doi: 10.3969/j.issn.1674-7445.2023154

Citation:

PDF( 514 KB)

Research progress in risk factors of post-transplantation diabetes mellitus

doi: 10.3969/j.issn.1674-7445.2023154

1.
Department of Organ Transplantation, the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China

More Information

Corresponding author: Yin Hao, Email: roytina0241032@hotmail.com
Received Date: 2023-08-02
Available Online: 2023-11-29
Publish Date: 2024-01-11

Abstract

Abstract

Solid organ transplantation has significantly prolonged the survival of patients with end-stage diseases. However, long-term use of immunosuppressants will increase the risk of post-transplantation diabetes mellitus (PTDM) in the recipients, thereby elevating the risk of infection, cardiovascular disease and death. In recent years, with persistent improvement of diagnostic criteria of PTDM, clinicians have deepened the understanding of this disease. Compared with type 2 diabetes mellitus, PTDM significantly differs in pathophysiological characteristics and clinical progression. Hence, different treatment strategies should be adopted. Early identification of risk factors of organ transplant recipients, early diagnosis and intervention are of significance for improving the quality of life of recipients, prolonging the survival of grafts and reducing the fatality of recipients. Therefore, the diagnosis, incidence and risk factors of PTDM were reviewed in this article, aiming to provide reference for clinicians to deliver prompt diagnosis and intervention for PTDM.
- Organ transplantation,
- Post-transplantation diabetes mellitus,
- Calcineurin inhibitor,
- Mammalian target of rapamycin inhibitor,
- Glucocorticoid,
- Cytomegalovirus,
- Rejection,
- Single nucleotide polymorphism

FullText(HTML)

References(39)

References

[1]	DE LA FUENTE-MANCERA JC, FORADO-BENTAR I, FARRERO M. Management of long-term cardiovascular risk factors post organ transplant[J]. Curr Opin Organ Transplant, 2022, 27(1): 29-35. DOI: 10.1097/MOT.0000000000000950.
[2]	SHARIF A. Prevention of post-transplantation diabetes: small steps, big opportunities[J]. J Am Soc Nephrol, 2021, 32(8): 1833-1834. DOI: 10.1681/ASN.2021060777.
[3]	WANG Q, WU J, WANG X, et al. Risk factors of new-onset diabetes after renal transplantation and prognostic analysis[J]. Altern Ther Health Med, 2023, 29(2): 230-235.
[4]	中国康复医学会器官移植康复专业委员会. 成人实体器官移植后糖尿病管理专家共识[J]. 器官移植, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110. Organ Transplantation and Rehabilitation Committee of Chinese Medical Association of Rehabilitation. Expert consensus on diabetes mellitus after solid organ transplantation in adults[J]. Organ Transplant, 2023, 14(5): 623-642. DOI: 10.3969/j.issn.1674-7445.2023110.
[5]	HE J, YANG M, QUAN X, et al. Microbial and metabolic features in renal transplant recipients with post-transplantation diabetes mellitus[J]. Int J Urol, 2023, 30(6): 504-513. DOI: 10.1111/iju.15158.
[6]	陈荣鑫, 赖兴强, 张磊, 等. 肾移植受者发生移植后糖尿病的危险因素分析及预测模型的构建[J]. 器官移植, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012. CHEN RX, LAI XQ, ZHANG L, et al. Analysis of risk factors and establishment of prediction model for post transplantation diabetes mellitus in renal transplant recipients[J]. Organ Transplant, 2021, 12(3): 329-335. DOI: 10.3969/j.issn.1674-7445.2021.03.012.
[7]	WANG L, HUANG J, LI Y, et al. Postoperative fasting plasma glucose and family history diabetes mellitus can predict post-transplantation diabetes mellitus in kidney transplant recipients[J]. Endocrine, 2023, 81(1): 58-66. DOI: 10.1007/s12020-023-03374-y.
[8]	SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
[9]	LIN Y, MOK M, HARRISON J, et al. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: a systematic review[J]. Transplant Rev (Orlando), 2023, 37(1): 100729. DOI: 10.1016/j.trre.2022.100729.
[10]	HARREITER J, RODEN M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023)[J]. Wien Klin Wochenschr, 2023, 135(Suppl 1): 7-17. DOI: 10.1007/s00508-022-02122-y.
[11]	HECKING M, SHARIF A, ELLER K, et al. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics[J]. Transpl Int, 2021, 34(1): 27-48. DOI: 10.1111/tri.13783.
[12]	CHAITOU AR, VALMIKI S, VALMIKI M, et al. New-onset diabetes mellitus (NODM) after liver transplantation (lt): the ultimate non-diabetogenic immunosuppressive therapy[J]. Cureus, 2022, 14(3): e23635. DOI: 10.7759/cureus.23635.
[13]	JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
[14]	PAUCHET A, SCHWOTZER N, LAMINE F, et al. Post-transplantation diabetes in kidney transplant: from the diabetologist point of view[J]. Rev Med Suisse, 2020, 16(697): 1200-1205.
[15]	SHIVASWAMY V, BOERNER B, LARSEN J. Post-Transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61. DOI: 10.1210/er.2015-1084.
[16]	ZHANG Z, SUN J, GUO M, et al. Progress of new-onset diabetes after liver and kidney transplantation[J]. Front Endocrinol (Lausanne), 2023, 14: 1091843. DOI: 10.3389/fendo.2023.1091843.
[17]	REID L, BAXTER F, FORBES S. Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes[J]. Diabet Med, 2021, 38(7): e14570. DOI: 10.1111/dme.14570.
[18]	KIM NG, SHARMA A, SAAB S. Cardiovascular and metabolic disease in the liver transplant recipient[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101683. DOI: 10.1016/j.bpg.2020.101683.
[19]	DE VRIES DK, LINDEMAN JH, RINGERS J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation[J]. Am J Transplant, 2011, 11(5): 1064-1070. DOI: 10.1111/j.1600-6143.2011.03466.x.
[20]	NAESENS M, LI L, YING L, et al. Expression of complement components differs between kidney allografts from living and deceased donors[J]. J Am Soc Nephrol, 2009, 20(8): 1839-1851. DOI: 10.1681/ASN.2008111145.
[21]	ABDELAZIZ TS, ALI AY, FATTHY M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta-analysis[J]. Curr Diabetes Rev, 2020, 16(6): 580-585. DOI: 10.2174/1573399815666190321144310.
[22]	中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002. Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14,28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
[23]	张岑, 王文妍, 文力. 类固醇相关糖尿病风险防范及诊治[J]. 临床药物治疗杂志, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004. ZHANG C, WANG WY, WEN L. Risk prevention and treatment of steroid-induced diabetes mellitus[J]. Clin Med J, 2023, 21(8): 18-21. DOI: 10.3969/j.issn.1672-3384.2023.08.004.
[24]	WOODLE ES, FIRST MR, PIRSCH J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy[J]. Ann Surg, 2008, 248(4): 564-577. DOI: 10.1097/SLA.0b013e318187d1da.
[25]	WEBSTER AC, WOODROFFE RC, TAYLOR RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data[J]. BMJ, 2005, 331(7520): 810. DOI: 10.1136/bmj.38569.471007.AE.
[26]	NOGUEIRAS-ÁLVAREZ R, MORA-CUESTA VM, CIFRIÁN-MARTÍNEZ JM, et al. Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain[J]. Sci Rep, 2022, 12(1): 21207. DOI: 10.1038/s41598-022-25445-2.
[27]	WANG Z, JIANG Z, LU R, et al. Formulation strategies to provide oxygen-release to contrast local hypoxia for transplanted islets[J]. Eur J Pharm Biopharm, 2023, 187: 130-140. DOI: 10.1016/j.ejpb.2023.04.015.
[28]	VAN LAECKE S, VAN BIESEN W, VERBEKE F, et al. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation[J]. Am J Transplant, 2009, 9(9): 2140-2149. DOI: 10.1111/j.1600-6143.2009.02752.x.
[29]	LOMBARDI Y, FRANÇOIS H. Belatacept in kidney transplantation: what are the true benefits? a systematic review[J]. Front Med (Lausanne), 2022, 9: 942665. DOI: 10.3389/fmed.2022.942665.
[30]	ARAKI M, FLECHNER SM, ISMAIL HR, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs[J]. Transplantation, 2006, 81(3): 335-341. DOI: 10.1097/01.tp.0000195770.31960.18.
[31]	CAMAYA I, DONNELLY S, O'BRIEN B. Targeting the PI3K/Akt signaling pathway in pancreatic β-cells to enhance their survival and function: an emerging therapeutic strategy for type 1 diabetes[J]. J Diabetes, 2022, 14(4): 247-260. DOI: 10.1111/1753-0407.13252.
[32]	OTHMAN N, GHEITH O, AL-OTAIBI T, et al. Effect of structured diabetes education on diabetic angiopathies among kidney transplant recipients with posttransplant diabetes: kuwait experience[J]. Exp Clin Transplant, 2022, 20(Suppl 1): 46-54. DOI: 10.6002/ect.MESOT2021.O19.
[33]	DELOS SANTOS RB, HAGOPIAN JC, CHEN L, et al. Sitagliptin versus placebo to reduce the incidence and severity of posttransplant diabetes mellitus after kidney transplantation-a single-center, randomized, double-blind controlled trial[J]. Transplantation, 2023, 107(5): 1180-1187. DOI: 10.1097/TP.0000000000004373.
[34]	KATHIRVEL M, MALLICK S, SETHI P, et al. Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)[J]. HPB (Oxford), 2021, 23(5): 666-674. DOI: 10.1016/j.hpb.2020.09.012.
[35]	尚梦月, 陈永忠, 保洁, 等. 慢性乙型肝炎合并代谢相关脂肪性肝病的临床及病理特点分析[J]. 中华肝脏病杂志, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113- 20220701-00362. SHANG MY, CHEN YZ, BAO J, et al. Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease[J]. Chin J Hepatol, 2023, 31(2): 126-132. DOI: 10.3760/cma.j.cn501113-20220701-00362.
[36]	张绍丽, 曹毛毛, 杨帆, 等. 1990—2019年中国人群肝癌各病因疾病负担变化趋势分析[J]. 中华消化外科杂志, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610- 20221112-00687. ZHANG SL, CAO MM, YANG F, et al. Analysis of the change trend of etiological burden of disease of liver cancer in the Chinese population from 1990 to 2019[J]. Chin J Dig Surg, 2023, 22(1): 122-130. DOI: 10.3760/cma.j.cn115610-20221112-00687.
[37]	PISANO G, FRACANZANI AL, CACCAMO L, et al. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study[J]. World J Gastroenterol, 2016, 22(40): 8869-8882. DOI: 10.3748/wjg.v22.i40.8869.
[38]	PATIL DT, YERIAN LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation[J]. Liver Transpl, 2012, 18(10): 1147-1153. DOI: 10.1002/lt.23499.
[39]	ANDRADE AR, BITTENCOURT PL, CODES L, et al. New onset diabetes and non-alcoholic fatty liver disease after liver transplantation[J]. Ann Hepatol, 2017, 16(6): 932-940. DOI: 10.5604/01.3001.0010.5285.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (181) PDF downloads(28)

Research progress in risk factors of post-transplantation diabetes mellitus

doi: 10.3969/j.issn.1674-7445.2023154

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research progress in risk factors of post-transplantation diabetes mellitus

doi: 10.3969/j.issn.1674-7445.2023154

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content